AI-generated summary
The authors studied infrared photobiomodulation in preterm rats, comparing control animals with groups receiving 660 nm or 830 nm light, and measured surfactant proteins and cell safety tests. They report that 660 nm treatment significantly increased surfactant B, C and D levels without evidence of cytotoxic or phototoxic damage. The work is in animals and cells, so the authors state that clinical studies in human preterm infants are needed.
- Participants
- 68
- Who or what was studied
- Preterm Sprague-Dawley rats
- Wavelengths
- 660, 830 nm
- Limits stated in the abstract
- The study was conducted in preterm rats and H-6053 cells, and the authors state that human clinical investigation is needed to validate the findings.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm, 830 nm
- Power
- 30 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Control group, Fluence. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.